Other
Chorioretinitis
6
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Chorioretinitis is an early-stage landscape with 6 programs across 3 companies. The most active players are Pfizer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Quince Therapeutics S.p.A.. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 11
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
2
clinical trials
Unknown status1 · 50%
Completed1 · 50%
Clinical Trials
Trial Activity
SD-OCT Guided Treatment of Fungal Chorioretinitis
Unknown status·—·N/A·NCT04947592·10 enrolled
Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1/2·NCT01552044·17 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)